S&P 500   4,191.98
DOW   33,426.63
QQQ   336.51
Mount Etna volcano erupts, raining ash on Catania, forcing flight suspension at local airport
This MMJ Stock Needs To Be At The Top Of Your Radar! (Ad)
China tells tech manufacturers to stop using Micron chips, stepping up feud with United States
Stock market today: Asian shares mostly rise despite worries about US debt talks
This MMJ Stock Needs To Be At The Top Of Your Radar! (Ad)
SpaceX launches two Saudi astronauts on private flight to space station
Civil rights groups warn tourists about Florida in wake of 'hostile' laws
Central Bank: “Final stage” beginning now (Ad)
South Korean, German leaders agree to cooperate on supply chains, North Korea
Animal rights activists protest octopus farm plans in Spain
S&P 500   4,191.98
DOW   33,426.63
QQQ   336.51
Mount Etna volcano erupts, raining ash on Catania, forcing flight suspension at local airport
This MMJ Stock Needs To Be At The Top Of Your Radar! (Ad)
China tells tech manufacturers to stop using Micron chips, stepping up feud with United States
Stock market today: Asian shares mostly rise despite worries about US debt talks
This MMJ Stock Needs To Be At The Top Of Your Radar! (Ad)
SpaceX launches two Saudi astronauts on private flight to space station
Civil rights groups warn tourists about Florida in wake of 'hostile' laws
Central Bank: “Final stage” beginning now (Ad)
South Korean, German leaders agree to cooperate on supply chains, North Korea
Animal rights activists protest octopus farm plans in Spain
S&P 500   4,191.98
DOW   33,426.63
QQQ   336.51
Mount Etna volcano erupts, raining ash on Catania, forcing flight suspension at local airport
This MMJ Stock Needs To Be At The Top Of Your Radar! (Ad)
China tells tech manufacturers to stop using Micron chips, stepping up feud with United States
Stock market today: Asian shares mostly rise despite worries about US debt talks
This MMJ Stock Needs To Be At The Top Of Your Radar! (Ad)
SpaceX launches two Saudi astronauts on private flight to space station
Civil rights groups warn tourists about Florida in wake of 'hostile' laws
Central Bank: “Final stage” beginning now (Ad)
South Korean, German leaders agree to cooperate on supply chains, North Korea
Animal rights activists protest octopus farm plans in Spain
S&P 500   4,191.98
DOW   33,426.63
QQQ   336.51
Mount Etna volcano erupts, raining ash on Catania, forcing flight suspension at local airport
This MMJ Stock Needs To Be At The Top Of Your Radar! (Ad)
China tells tech manufacturers to stop using Micron chips, stepping up feud with United States
Stock market today: Asian shares mostly rise despite worries about US debt talks
This MMJ Stock Needs To Be At The Top Of Your Radar! (Ad)
SpaceX launches two Saudi astronauts on private flight to space station
Civil rights groups warn tourists about Florida in wake of 'hostile' laws
Central Bank: “Final stage” beginning now (Ad)
South Korean, German leaders agree to cooperate on supply chains, North Korea
Animal rights activists protest octopus farm plans in Spain

Best Stocks Under $10.00 Right Now

Best Stocks Under $10.00

A common mistake among novice investors is confusing an undervalued stock with a cheap stock. When a stock trades under $5 (often called penny stocks), it can be easy for an investor to understand why the stock carries such a low price. But when a stock trades below $10, a little more research is required. This is particularly true when the broader market is in a sell-off. Before attempting to buy stocks that are trading for less than 10 dollars, there are some important things to know.

If you’re an experienced investor this is just a basic review. But if you’re a relatively new investor this may help answer a lot of questions.

To understand why buying stocks under $10 can come with an elevated risk you need to understand how a company’s stock price is calculated. There are two data points to look for.

The first is a company’s market capitalization (or market cap). That is a rough estimation of how much a company is worth. The second number is the number of outstanding shares (also called shares outstanding – the meaning is the same). This is, as the name suggests, the number of common shares available to be bought.

To calculate a company’s stock price, you divide the company’s current market capitalization by its number of outstanding shares.

Here’s an example that keeps the math easy. A stock that is valued at $100 million and has 1 million outstanding shares has a share price of $100. But a stock that is valued at $100 million and has 100 million outstanding shares has a share price of $10.

The important thing to take away from that example is a stock’s price does not necessarily reflect the market value of the company.

Now here’s a real world example. On March 27, General Electric (NYSE:GE) had a market cap of $66.37 billion. The company had 8.74 billion outstanding shares. When you divide the market cap by the outstanding shares you get 7.59.

66.37/8.74 = 7.59

This means at that moment, one share of GE stock was valued at $7.59.

The simple answer is “Of course you should.” A common fallacy among even the most experienced investors is failing to understand the difference between a stock that is cheap and one that is undervalued. It’s an interesting aspect of human psychology. A stock that is trading at $200 could decline by 25% and investors will swoop in to buy it “on sale”. But if a $12 stock drops 20% it becomes untouchable.

The problem with this approach is it assumes that a high price is good and a low price is bad. And in fairness, that can be true. Many stocks that trade under $10 do so because they present obvious and fundamentally problematic issues that are suppressing their growth.

So if you’re an investor who is looking to buy stocks under $10 is be sure you’re ready, and able, to do some research. Simply throwing your hard-earned money at a stock because you’ve heard the mantra “buy low, sell high” is foolish.

But the same can be said of investing in any stock. And if you’re reading this article, I hope you already understand that stocks over time can be an excellent and sound investment. Stock prices, no matter the price, can fluctuate wildly. But over time, investing in stocks has proven to be the most reliable path to reaching your financial goals.

And the simple truth is that a stock that is trading under $10 can offer you the ability to make huge gains. But that is, if you know what to look for. Fortunately, in this article, we’ve done a lot of that research for you.

But there is one caveat about investing in stocks under $10. This should only make up a small portion of the stock portion of your portfolio. The majority of your investment in equities (another name for stocks) should focus on solid, stable companies. And depending on your investment style, you should look for companies that pay a dividend.

You should also not invest in stocks under $10 to replace money you have set aside in bonds or cash. This should be money that you are already investing in the market.

The reward of buying stocks under $10 is the opportunity for growth. If you can buy 1000 shares of a stock that is trading at $8, you would only need the stock to increase in value by $8 to double your investment. If you were

That, however, is easier said than done. And many investors have seen that $8,000 investment evaporate as they bought shares of a falling knife. Still, if investors can find the right stock, stocks under $10 are one of the best ways to capture a significant gain without a large investment.

That brings up a second point. Stocks under $10 are more accessible for investors without a lot of money to put into the market. Robinhood and other trading apps are designed on this principle. If you only have a small amount of money to invest, you don’t have to put all your eggs in one basket. In practical terms, and investor with $10,000 to invest could buy over 150 shares a stock that is currently trading below $7 a share.

This also makes stocks under $10 a great option for diversification. Not only can you look at different sectors, but you can also dabble in international stocks.

Here are some of the most common risks of buying stocks under $10:

  • Share dilution - Generally, the number of outstanding shares is driven by simple supply and demand. A company that issues a solid earnings report, or comes out with a new product, etc. will see their outstanding shares decline because there will be more buyers than sellers.

    In other words, the stock is harder to buy. If an investor wants to buy it, a seller will demand a higher price to let their shares go. And when there are more sellers than buyers, there will be a higher number of outstanding shares. In other words, sellers have to accept a lower price for the shares they purchased to entice a buyer to buy.

    However, when a company gets into financial trouble, it becomes difficult for them to get loans. When a company has limited free cash flow (FCF), they are seen as a credit risk. This simply means lenders believe there is a high probability that the company will default on the loan.

    When this happens, one strategy they may execute is to issue more shares. This almost always dilutes the value of the existing shares, which in turn drives the price down further.

  • Increased competition - Young startup companies often have a first mover advantage. Because they are creating a new market, they have no competition and have no price pressure. However, as more competitors enter the market, a company may face pressure both on the price they charge and their profit margin. If the company is slow to adapt to the competition, their stock price may sink to extremely low levels.

  • The company operates in a cyclical industry - A retailer may see their stock spike during the holiday season as investors anticipate greater revenue and profit. However, for the remainder of the year, the company may not be able to sustain that revenue. That’s another reason the stock may sink.

  • The stock is low- to no-growth stock - If you look at the price history of a stock, it may just trade in a specific range. In that case, a stock under $10 may still be a worthwhile investment if it pays a nice dividend.

If you’ve followed this article and understand both the pros and cons of stocks under $10, let’s take a look at how you can put that information to work in the middle of one of the greatest stock sell-offs in history.

On the one hand, there are a number of quality companies that have seen their share price reach uncomfortably low levels. But some of these stocks are in industries like hospitality that have been particularly affected by the coronavirus. And while these stocks are generally perceived to see increased, pent-up demand once the coronavirus threat recedes, it may be some time before this increased demand shows up in the stock price.

Value investing opportunities do exist—if you're looking in the right places. Putting together a list of the best stocks under $10.00 requires investors to do their homework. At a price of under $10, these companies are not penny stocks. In fact many companies have a large market cap. But just because a stock is trading for a low price doesn’t make it a great value.

One of the biggest assets an investor can have is time. If you’ve done your due diligence and believe in the overall financial health and direction of the company, buying stocks under $10 can be very profitable. If you have the time and patience to hold the stock through many economic cycles, here are some stocks to consider.

 


JD Sports Fashion stock logo

#1 - JD Sports Fashion

OTCMKTS:JDSPY
Stock Price: $2.39 (+$0.04)
Average Trading Volume: 2,469 shares
Consensus Rating: Strong Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $203.33 (8,407.7% Upside)
JD Sports Fashion Plc retails and distributes sports fashion wear and outdoor clothing and equipment. It operates through the Sports Fashion and Outdoor segments. The Sports Fashion segment consists of JD Sports Fashion Plc, John David Sports Fashion (Ireland) Limited, Spodis SA, Champion Sports Ireland, JD Sprinter Holdings 2010 SL, JD Sports Fashion BV, JD Sports Fashion Germany GmbH, JD Sports Fashion SRL, Duffer of St George Limited, Topgrade Sportswear Limited, Kooga Rugby Limited, Focus Brands Limited, Kukri Sports Limited, Source Lab Limited, R.D. Scott Limited, Tessuti Group Limited, Nicholas Deakins Limited, Cloggs Online Limited, Ark Fashion Limited and Mainline Menswear Limited. The Outdoor segment consists of Blacks Outdoor Retail Ltd. Tiso Group Ltd and ActivInstinct Limited. The company was founded by John Carruthers Wardle and David Martin Makin in 1981 and is headquartered in Bury, the United Kingdom.
Ocular Therapeutix stock logo

#2 - Ocular Therapeutix

NASDAQ:OCUL
Stock Price: $6.46 (+$0.09)
PE Ratio: -5.43
Market Cap: $500.84 million
Average Trading Volume: 1.30 million shares
Consensus Rating: Buy (4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $12.80 (98.1% Upside)
Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.
InflaRx stock logo

#3 - InflaRx

NASDAQ:IFRX
Stock Price: $4.57 (+$0.20)
PE Ratio: -7.37
Market Cap: $204.28 million
Average Trading Volume: 1.65 million shares
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $14.00 (206.3% Upside)
InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a and its receptor C5aR. Its primary product candidate is Vilobelimab. The company was founded by Niels Christoph Riedemann, Renfeng Guo, and Nicolas Fulpius in December 2007 and is headquartered in Jena, Germany.
CymaBay Therapeutics stock logo

#4 - CymaBay Therapeutics

NASDAQ:CBAY
Stock Price: $9.11 (+$0.06)
PE Ratio: -7.72
Market Cap: $888.32 million
Average Trading Volume: 1.65 million shares
Consensus Rating: Buy (7 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $14.57 (59.9% Upside)
CymaBay Therapeutics, Inc. engages in the provision and development of access to therapies for patients with liver and other chronic diseases with high unmet medical needs. Its products pipeline includes Seladelpar, MBX-2982, CB-0406, and CB-001. The company was founded on October 5, 1988 and is headquartered in Newark, CA.
Taseko Mines stock logo

#5 - Taseko Mines

NYSEAMERICAN:TGB
Stock Price: $1.37 (-$0.02)
PE Ratio: -17.13
Market Cap: $395.14 million
Average Trading Volume: 1.21 million shares
Consensus Rating: Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $2.73 (99.3% Upside)
Taseko Mines Ltd. operates as a mining company engaged in the acquisition, development, and operation of mineral deposits. It holds interest in the Gibraltar, Florence Copper, Aley Niobium, Yellowhead, New Prosperity, and Harmony projects. The company was founded on April 15, 1966 and is headquartered in Vancouver, Canada.
CES Energy Solutions stock logo

#6 - CES Energy Solutions

OTCMKTS:CESDF
Stock Price: $1.74
PE Ratio: 6.01
Average Trading Volume: 12,339 shares
P/E Ratio: 6.0
Dividend Yield: 6.45%
Consensus Rating: Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $4.28 (146.0% Upside)
CES Energy Solutions Corp., together with its subsidiaries, designs, implements, and manufactures advanced consumable fluids and specialty chemicals. It provides solutions for drill-bit, point of completion and stimulation, wellhead and pump-jack, and pipeline and midstream markets. The company's solutions include corrosion inhibitors, demulsifiers, H2S scavengers, paraffin control products, surfactants, scale inhibitors, biocides, and other specialty products. It also designs and implements drilling fluid systems and completion solutions for oil and gas producers; designs and manufactures production and specialty chemicals for use in the oil and natural gas production markets, the stimulation and fracturing markets, and the pipeline and midstream markets; and operates trucks and trailers to transport products in the oil and gas industry. In addition, the company provides environmental consulting, water management services, and drilling fluids waste disposal services primarily to oil and gas producers; and laboratory services. It serves oil and natural gas industry, including multinational producers, intermediate oil and natural gas operators, independent juniors, and joint ventures, as well as pipeline and mid-stream markets in western Canada and the United States. The company was formerly known as Canadian Energy Services & Technology Corp. and changed its name to CES Energy Solutions Corp. in June 2017. CES Energy Solutions Corp. was incorporated in 1986 and is headquartered in Calgary, Canada.
ORIC Pharmaceuticals stock logo

#7 - ORIC Pharmaceuticals

NASDAQ:ORIC
Stock Price: $4.96
PE Ratio: -2.26
Market Cap: $223.65 million
Average Trading Volume: 214,551 shares
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $13.20 (166.1% Upside)
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. It has a license and collaboration agreement with Voronoi Inc.; and a license agreement with Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
Longboard Pharmaceuticals stock logo

#8 - Longboard Pharmaceuticals

NASDAQ:LBPH
Stock Price: $9.24 (-$0.26)
PE Ratio: -3.60
Market Cap: $212.23 million
Average Trading Volume: 63,640 shares
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $17.40 (88.3% Upside)
Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing transformative medicines for neurological diseases. The company's lead product candidate is LP352, which is in a Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. Its preclinical product candidates include LP659 and LP143, which focuses on developing therapies for multiple neurological diseases. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California.
Stereotaxis stock logo

#9 - Stereotaxis

NYSEAMERICAN:STXS
Stock Price: $2.25 (+$0.56)
PE Ratio: -8.33
Market Cap: $181.53 million
Average Trading Volume: 224,166 shares
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $5.10 (126.7% Upside)
Stereotaxis, Inc. designs, manufactures and markets robotic magnetic navigation systems for use in a hospital's interventional surgical suite to enhance the treatment of arrhythmias and coronary artery disease. Its products include the Genesis RMN System, the Odyssey Solution, and related devices. The firm also offers the Stereotaxis Imaging Model S x-ray System. The company was founded in June 1990 and is headquartered in St. Louis, MO.
Saipem stock logo

#10 - Saipem

OTCMKTS:SAPMY
Stock Price: $0.25 (-$0.04)
PE Ratio: 0.77
Average Trading Volume: 41,684 shares
P/E Ratio: 0.8
Consensus Rating: Buy (8 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $1.95 (689.2% Upside)
Saipem SpA provides integrated basic and detailed onshore engineering, procurement, project management, and construction services mainly to the oil and gas, complex civil and marine infrastructure, and environmental market sectors. It operates through the following business segments: Offshore Engineering and Construction; Onshore Engineering and Construction; Offshore Drilling; and Onshore Drilling. The Offshore Engineering and Construction segment includes platforms, pipelines, subsea field developments, MMO or Maintenance, Modification, and Operations activities, and the execution of large-scale offshore projects. The Onshore Engineering and Construction segment designs and constructs hydrocarbon production facilities, hydrocarbon treatment facilities, and large onshore treatment and transportation systems and facilities. The Offshore Drilling segment consists of a fleet of vessels for deep water, mid-water, high specifications jack-up, and standard jack-up operations. The Onshore Drilling segment comprises a fleet of drilling rigs for wells in Italy and abroad. The company was founded in 1957 and is headquartered in San Donato Milanese, Italy.
DarioHealth stock logo

#11 - DarioHealth

NASDAQ:DRIO
Stock Price: $3.75 (-$0.02)
PE Ratio: -2.60
Market Cap: $98.85 million
Average Trading Volume: 154,219 shares
Consensus Rating: Buy (4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $11.40 (204.0% Upside)
DarioHealth Corp. is a digital therapeutics company, which engages in the research, development, and sale of pharmaceutical products. It offers a monitoring device, mobile application, and data services for diabetes management. Its solutions include MyDario, Daro Engage, and Dario Intelligence. The company was founded by Oren Fuerst, Shoshana Friedman, David Weintraub, Dov Oppenheim, and Shilo Ben Zeev on August 11, 2011 and is headquartered in New York, NY.
Roivant Sciences stock logo

#12 - Roivant Sciences

NASDAQ:ROIV
Stock Price: $9.32 (+$0.23)
PE Ratio: -5.24
Market Cap: $7.07 billion
Average Trading Volume: 2.90 million shares
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $12.80 (37.3% Upside)
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.
Integra Resources stock logo

#13 - Integra Resources

NYSEMKT:ITRG
Stock Price: $0.50 (+$0.01)
PE Ratio: -1.79
Market Cap: $38.71 million
Average Trading Volume: 100,814 shares
Consensus Rating: Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $2.58 (416.0% Upside)
Integra Resources Corp., a mineral resources company, engages in the acquisition, exploration, and development of mineral properties in the Americas. It primarily focuses on the development of DeLamar project that consists of DeLamar and Florida Mountain gold and silver deposits comprising 790 unpatented lode, placer, and millsite claims, as well as 16 tax parcels covering an area of approximately 8,673 hectares located in the Owyhee County, south western Idaho. The company was formerly known as Mag Copper Limited and changed its name to Integra Resources Corp. in August 2017. Integra Resources Corp. was incorporated in 1997 and is headquartered in Vancouver, Canada.
Arcutis Biotherapeutics stock logo

#14 - Arcutis Biotherapeutics

NASDAQ:ARQT
Stock Price: $9.47 (+$0.02)
PE Ratio: -1.66
Market Cap: $581.65 million
Average Trading Volume: 1.03 million shares
Consensus Rating: Buy (7 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $46.17 (387.5% Upside)
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
OmniAb stock logo

#15 - OmniAb

NASDAQ:OABI
Stock Price: $3.86 (-$0.06)
Market Cap: $446.22 million
Average Trading Volume: 640,177 shares
Consensus Rating: Buy (9 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $10.00 (159.1% Upside)
OmniAb, Inc., a biotechnology company, provides therapeutic antibody discovery technologies in the United States. The company's discovery platform provides industry partners access to the diverse antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur that features unique structural attributes of cow antibodies for complex targets. The company was founded in 2012 and is headquartered in Emeryville, California.
Alpine Immune Sciences stock logo

#16 - Alpine Immune Sciences

NASDAQ:ALPN
Stock Price: $9.50 (+$0.90)
PE Ratio: -5.56
Market Cap: $455.72 million
Average Trading Volume: 95,101 shares
Consensus Rating: Buy (4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $16.40 (72.6% Upside)
Alpine Immune Sciences, Inc. is a development-stage pharmaceutical company, which engages in the discovery of protein-based immunotherapies to treat cancer and autoimmune and inflammatory diseases. Its product pipeline includes inflammatory diseases, immuno-oncology, and engineered cellular therapies. The company was founded in March 2007 and is headquartered in Seattle, WA.
SilverCrest Metals stock logo

#17 - SilverCrest Metals

NYSEMKT:SILV
Stock Price: $6.76 (-$0.02)
PE Ratio: 15.02
Market Cap: $998.23 million
Average Trading Volume: 920,697 shares
P/E Ratio: 15.0
Consensus Rating: Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $11.70 (73.1% Upside)
SilverCrest Metals Inc. explores for and develops precious metal properties in Mexico. The company primarily explores for silver and gold properties. Its principal property includes the Las Chispas project that consists of 28 concessions totaling of approximately 1,401 hectares located in Sonora, Mexico. The company was incorporated in 2015 and is headquartered in Vancouver, Canada.
Rain Oncology stock logo

#18 - Rain Oncology

NASDAQ:RAIN
Stock Price: $9.93 (+$0.17)
PE Ratio: -3.82
Market Cap: $361.09 million
Average Trading Volume: 232,053 shares
Consensus Rating: Buy (9 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $16.44 (65.6% Upside)
Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing milademetan which is in Phase 3 clinical trial for liposarcoma, Phase II clinical trial for solid tumors, and Phase II clinical trial for intimal sarcoma, as well as RAD52 which is in preclinical trials for tumors, including breast, ovarian, pancreatic, prostate, and other cancers. Rain Therapeutics Inc. was incorporated in 2017 and is headquartered in Newark, California.
CarParts.com stock logo

#19 - CarParts.com

NASDAQ:PRTS
Stock Price: $4.20 (-$0.14)
PE Ratio: -105.00
Market Cap: $236.59 million
Average Trading Volume: 720,352 shares
Consensus Rating: Buy (2 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $12.00 (185.7% Upside)
CarParts.com, Inc. operates as an online provider of aftermarket auto parts and accessories in the United States and the Philippines. Its products include Collision Parts, Engine Parts, Performance Parts and Accessories. The firm also sells auto parts to collision repair shops, markets Kool-Vue products to auto parts wholesale distributor, and aftermarket catalytic converters under the Evan Fischer brand. Its flagship Websites include www.carparts.com, www.jcwhitney.com, www.autopartswarehouse.com and www.usautoparts.com. The company was founded by Sol Khazani and Mehran Nia in 1995 and is headquartered in Carson, CA.
D-Wave Quantum stock logo

#20 - D-Wave Quantum

NYSE:QBTS
Stock Price: $0.48 (-$0.13)
Market Cap: $61.56 million
Average Trading Volume: 1.69 million shares
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $5.00 (932.8% Upside)
D-Wave Quantum Inc. develops and delivers quantum computing systems, software, and services worldwide. The company offers Advantage, a fifth-generation quantum computer; Launch, a quantum computing onboarding service; Ocean a full suite of open-source programming tools; and Leap, a cloud-based service that provides real-time access to a live quantum computer, as well as access to Advantage, hybrid solvers, the Ocean software development kit, live code, demos, learning resources, and a vibrant developer community. It also provides D-Wave Launch, a quantum professional service that guides enterprises from problem discovery through in-production application deployment. The company's quantum solutions are used in artificial intelligence, materials sciences, drug discovery, scheduling, cybersecurity, fault detection, and financial modeling. It serves manufacturing and logistics, financial services, life sciences, and other industries. D-Wave Quantum Inc. is based in Burnaby, Canada.
Fusion Pharmaceuticals stock logo

#21 - Fusion Pharmaceuticals

NASDAQ:FUSN
Stock Price: $4.29 (+$0.04)
PE Ratio: -2.16
Market Cap: $273.92 million
Average Trading Volume: 263,494 shares
Consensus Rating: Buy (7 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $8.67 (102.0% Upside)
Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to various targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company is also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it is progressing its earlier-stage product candidate, FPI-1966 into clinical development for the treatment of head and neck, and bladder cancers expressing fibroblast growth factor receptor. The company has a strategic collaboration agreement with AstraZeneca UK Limited to jointly discover, develop, and commercialize alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. Fusion Pharmaceuticals Inc. was incorporated in 2014 and is headquartered in Hamilton, Canada.
Endeavour Silver stock logo

#22 - Endeavour Silver

NYSE:EXK
Stock Price: $3.24 (-$0.01)
PE Ratio: -324.00
Market Cap: $620.49 million
Average Trading Volume: 2.52 million shares
Consensus Rating: Buy (4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $5.83 (80.0% Upside)
Endeavour Silver Corp. operates as a mineral company. It engages in the evaluation, acquisition, exploration, development and exploitation of precious metal properties in Mexico and Chile. The firm's projects include the Terronera property in Jalisco, the El Compas property, the Guanacevi Mine in Durango, Bolanitos Mines in Guanajuato, and the Parral project in Chihuahua, Mexico. The company was founded by Bradford James Cooke on March 11, 1981 and is headquartered in Vancouver, Canada.
Backblaze stock logo

#23 - Backblaze

NASDAQ:BLZE
Stock Price: $4.30 (+$0.10)
PE Ratio: -2.50
Market Cap: $147.49 million
Average Trading Volume: 102,817 shares
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $10.70 (148.8% Upside)
Backblaze, Inc., a storage cloud platform, provides businesses and consumers cloud services to store, use, and protect data in the United States and internationally. The company offers cloud services through a web-scale software infrastructure built on commodity hardware. It also provides Backblaze B2 Cloud Storage, which enables customers to store data, developers to build applications, and partners to expand their use cases. This service is offered as a consumption-based Infrastructure-as-a-Service (IaaS) and serves use cases, such as backups, multi-cloud, application development, and ransomware protection. In addition, the company offers Backblaze Computer Backup that automatically backs up data from laptops and desktops for businesses and individuals, which provides a subscription-based Software-as-a-Service and serves use cases, including computer backup, ransomware protection, theft and loss protection, and remote access. It serves the public cloud IaaS storage and Data-Protection-as-a-Service markets. The company was incorporated in 2007 and is headquartered in San Mateo, California.
Altus Power stock logo

#24 - Altus Power

NYSE:AMPS
Stock Price: $4.42 (-$0.42)
PE Ratio: -220.89
Market Cap: $707.18 million
Average Trading Volume: 1.18 million shares
Consensus Rating: Buy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $10.67 (141.3% Upside)
Altus Power, Inc., a clean electrification company, originates, develops, owns, and operates roof, ground, and carport-based photovoltaic solar energy generation and storage systems. The company serves commercial, industrial, public sector, and community solar customers. Altus Power, Inc. was founded in 2013 and is based in Stamford, Connecticut.
Caribou Biosciences stock logo

#25 - Caribou Biosciences

NASDAQ:CRBU
Stock Price: $4.34 (+$0.08)
PE Ratio: -2.44
Market Cap: $266.32 million
Average Trading Volume: 507,192 shares
Consensus Rating: Buy (4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $27.60 (535.9% Upside)
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. It has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California.

More Stock Ideas from MarketBeat

My Account -